+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 14Years - 45Years
FEMALE
ID06905210

Phase III Study Comparing a New Antiandrogenic Progestogen and Low-dose Estrogen Combination Versus Placebo for Treatment of Moderate Acne Vulgaris in Women

Led by Eurofarma Laboratorios S.A. · Updated on 2026-10-27

531

Participants Needed

18

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy and safety of a new concentration of a fixed-dose combination drug called EF190 in women with moderate acne vulgaris. This Phase III randomized, double-blind, placebo-controlled, adaptive, multicenter study aims to compare the experimental drug with a placebo over six 28-day treatment cycles in female participants aged 14 to 45 years. The study addresses moderate acne characterized by specific lesion counts and includes participants who have had acne for at least six months. Participants will be randomly assigned in a 21 ratio to receive either the experimental drug, containing cyproterone acetate 2 mg and ethinyl estradiol 0.02 mg in a 24 active plus 4 inactive tablet regimen, or a matching placebo. Both groups will receive treatment for six consecutive 28-day cycles alongside standard skin care. The treatment starts on the 28th day after menstruation. In addition to study drug administration, a subgroup will undergo extra assessments including acne questionnaires, ovarian activity tests, photographic documentation, and special lab and ultrasound exams. Participants will attend five in-person visits screening, randomization, and three follow-ups occurring on day 15 of each treatment cycle. They will also receive three phone calls during cycles 2, 4, and 5 to support adherence, monitor side effects, and ensure contraceptive use. Researchers will measure reductions in inflammatory and total acne lesions and changes in acne severity through clinical assessments and questionnaires. The study includes safety monitoring and aims to complete participation within about 24 weeks.

CONDITIONS

Brief Title

Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris

Research Team

N

Natalia Silva Di Gianni

T

Taís Mendonça dos Santos

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here